Aptevo Therapeutics Inc Financials

APVO

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Weak

1/9

Aptevo Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.99x

For every $1 of reported earnings, Aptevo Therapeutics Inc generates $0.99 in operating cash flow (-$23.8M OCF vs -$24.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

This page shows Aptevo Therapeutics Inc (APVO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

-$24.3M

YoY+14.3%

Aptevo Therapeutics Inc's EBITDA was -$24.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.3% from the prior year.

Free Cash Flow

N/A

Net Income

-$24.1M

YoY-38.6%

Aptevo Therapeutics Inc reported -$24.1M in net income in fiscal year 2024. This represents a decrease of 38.6% from the prior year.

EPS (Diluted)

$-87.38

Aptevo Therapeutics Inc earned $-87.38 per diluted share (EPS) in fiscal year 2024. This represents an increase of 96.2% from the prior year.

Cash & Debt

$8.7M

YoY-48.5%

5Y CAGR-6.9%

Aptevo Therapeutics Inc held $8.7M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

Aptevo Therapeutics Inc had 1M shares outstanding in fiscal year 2024. This represents an increase of 12096.4% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$14.4M

YoY-16.0%

5Y CAGR-10.3%

Aptevo Therapeutics Inc invested $14.4M in research and development in fiscal year 2024. This represents a decrease of 16.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

APVO Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	$3.1M-74.7%	$12.3M+185.3%	$4.3M-86.7%	$32.4M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$19.9M
Gross Profit	N/A	N/A	N/A	N/A	N/A	$12.5M
R&D Expenses	$14.4M-16.0%	$17.1M-4.3%	$17.9M-5.9%	$19.0M+6.4%	$17.9M-27.9%	$24.8M
SG&A Expenses	$10.2M-13.1%	$11.8M-15.2%	$13.9M-5.6%	$14.7M+5.4%	$14.0M-44.9%	$25.3M
Operating Income	-$24.6M+14.8%	-$28.9M-0.8%	-$28.6M-33.8%	-$21.4M+22.2%	-$27.5M+32.9%	-$41.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$24.1M-38.6%	-$17.4M-316.9%	$8.0M+128.2%	-$28.5M-60.3%	-$17.8M+56.1%	-$40.4M
EPS (Diluted)	$-87.38	$-2316.83	$1.57+125.9%	$-6.07	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q1'22	Q4'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$3.1M-15.0%	$3.7M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.0M+30.3%	$3.1M	N/A	$3.9M	N/A	$4.5M-8.0%	$4.9M+7.1%	$4.5M
SG&A Expenses	$3.6M+69.0%	$2.1M	N/A	$2.7M	N/A	$3.3M-14.3%	$3.9M+22.0%	$3.2M
Operating Income	-$7.6M-46.0%	-$5.2M	N/A	-$6.6M	N/A	-$7.8M-38.7%	-$5.6M-38.9%	-$4.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$7.5M-48.0%	-$5.1M	N/A	-$6.3M	N/A	-$7.6M+0.7%	-$7.7M-22.7%	-$6.3M
EPS (Diluted)	$-2.23	$-357.86	N/A	$-22.16	N/A	$-1.50+3.2%	$-1.55	N/A

APVO Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$15.6M-37.2%	$24.8M-27.4%	$34.2M-39.6%	$56.6M+5.7%	$53.5M+0.3%	$53.4M
Current Assets	$10.7M-44.1%	$19.1M-30.5%	$27.4M-47.8%	$52.6M+11.2%	$47.3M+57.6%	$30.0M
Cash & Equivalents	$8.7M-48.5%	$16.9M-25.3%	$22.6M-49.7%	$45.0M+12.7%	$40.0M+221.2%	$12.4M
Inventory	N/A	N/A	N/A	N/A	N/A	$6.1M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$7.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10.8M-14.1%	$12.6M-22.3%	$16.2M-70.7%	$55.4M+49.9%	$37.0M-11.1%	$41.6M
Current Liabilities	$6.2M-14.1%	$7.2M-17.0%	$8.7M-75.0%	$34.8M+139.1%	$14.5M-62.0%	$38.2M
Long-Term Debt	N/A	$0-100.0%	$1.5M-60.7%	$3.7M-86.9%	$28.2M	N/A
Total Equity	$4.8M-61.1%	$12.2M-32.0%	$18.0M+1378.1%	$1.2M-92.7%	$16.6M+40.1%	$11.8M
Retained Earnings	-$247.6M-10.8%	-$223.4M-8.5%	-$206.0M+3.7%	-$214.1M-15.3%	-$185.6M-10.6%	-$167.9M

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q1'22	Q4'21
Total Assets	$27.0M+73.2%	$15.6M-37.2%	$24.8M-8.4%	$27.1M-20.7%	$34.2M+8.0%	$31.7M-29.9%	$45.2M-20.2%	$56.6M
Current Assets	$22.6M+112.5%	$10.7M-44.1%	$19.1M-9.8%	$21.1M-23.0%	$27.4M+11.5%	$24.6M-40.9%	$41.7M-20.7%	$52.6M
Cash & Equivalents	$21.1M+141.7%	$8.7M-48.5%	$16.9M-11.5%	$19.1M-15.6%	$22.6M+2.2%	$22.1M-36.7%	$35.0M-22.3%	$45.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$9.6M-11.4%	$10.8M-14.1%	$12.6M+1.7%	$12.4M-23.6%	$16.2M+1.9%	$15.9M-68.8%	$51.1M-7.8%	$55.4M
Current Liabilities	$5.6M-9.6%	$6.2M-14.1%	$7.2M+5.7%	$6.8M-21.5%	$8.7M+11.8%	$7.8M-67.4%	$23.9M-31.4%	$34.8M
Long-Term Debt	N/A	N/A	$0	$0-100.0%	$1.5M-23.8%	$1.9M	N/A	$3.7M
Total Equity	$17.4M+265.8%	$4.8M-61.1%	$12.2M-17.0%	$14.7M-18.1%	$18.0M+14.0%	$15.8M+367.9%	-$5.9M-583.9%	$1.2M
Retained Earnings	-$269.2M-8.7%	-$247.6M-10.8%	-$223.4M-2.7%	-$217.5M-5.6%	-$206.0M-2.3%	-$201.4M+9.2%	-$221.8M-3.6%	-$214.1M

APVO Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$23.8M-102.8%	-$11.7M+44.2%	-$21.0M+3.0%	-$21.7M+26.1%	-$29.3M+30.8%	-$42.4M
Capital Expenditures	N/A	N/A	$29K-95.9%	$713K+710.2%	$88K-42.5%	$153K
Free Cash Flow	N/A	N/A	-$21.1M+6.0%	-$22.4M+23.9%	-$29.4M+30.9%	-$42.5M
Investing Cash Flow	$0	$0+100.0%	-$29K+95.9%	-$713K-102.5%	$28.0M+584.2%	$4.1M
Financing Cash Flow	$15.6M+160.0%	$6.0M+329.3%	-$2.6M-110.0%	$26.2M+9.6%	$23.9M+18.5%	$20.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q1'22	Q4'21
Operating Cash Flow	-$6.7M-16.1%	-$5.8M-9.6%	-$5.3M+15.8%	-$6.2M-5.1%	-$5.9M+13.9%	-$6.9M-34.8%	-$5.1M-31.9%	-$3.9M
Capital Expenditures	N/A	N/A	N/A	N/A	$0-100.0%	$4K	N/A	$118K
Free Cash Flow	N/A	N/A	N/A	N/A	-$5.9M+13.9%	-$6.9M	N/A	-$4.0M
Investing Cash Flow	N/A	N/A	N/A	N/A	$0+100.0%	-$4K	N/A	-$118K
Financing Cash Flow	$18.3M+172.9%	$6.7M+120.6%	$3.0M-29.9%	$4.3M-27.6%	$6.0M+1299.6%	-$500K+89.9%	-$4.9M-60.5%	-$3.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

APVO Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	38.5%
Operating Margin	N/A	N/A	-919.8%-745.6pp	-174.1%+464.0pp	-638.1%-511.7pp	-126.3%
Net Margin	N/A	N/A	257.8%+489.3pp	-231.5%+180.4pp	-411.9%-287.2pp	-124.8%
Return on Equity	N/A	N/A	44.7%	N/A	N/A	N/A
Return on Assets	-154.8%-84.7pp	-70.1%-93.5pp	23.5%+73.7pp	-50.3%-17.1pp	-33.1%+42.6pp	-75.7%
Current Ratio	1.72-0.9	2.64-0.5	3.15+1.6	1.51-1.7	3.25+2.5	0.78
Debt-to-Equity	2.28+2.3	0.00-0.1	0.08-3.0	3.05+1.3	1.70-1.8	3.51
FCF Margin	N/A	N/A	-676.0%-493.8pp	-182.2%+500.3pp	-682.4%-551.2pp	-131.2%

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q1'22	Q4'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	-180.2%-70.0pp	-110.2%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	-247.2%-76.0pp	-171.1%
Return on Equity	N/A	N/A	N/A	11.9%	N/A	121.5%	N/A	N/A
Return on Assets	-28.0%+5.7pp	-33.7%	N/A	-23.4%	N/A	-24.1%-7.1pp	-17.0%-6.0pp	-11.1%
Current Ratio	4.03+2.3	1.72-0.9	2.64-0.5	3.09-0.1	3.150.0	3.16+1.4	1.75+0.2	1.51
Debt-to-Equity	0.55-1.7	2.28+2.3	0.000.0	0.00-0.1	0.08-0.0	0.12+8.8	-8.68-11.7	3.05
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-109.1%

Similar Companies

Xenetic Biosciences Inc XBIO

$5.0M

GRI Bio GRI

$3.3M

Onconetix ONCO

$1.2M

Oragenics OGEN

$2.7M

Quoin Pharmaceuticals Ltd QNRX

$13.6M

Frequently Asked Questions

Is Aptevo Therapeutics Inc profitable?

No, Aptevo Therapeutics Inc (APVO) reported a net income of -$24.1M in fiscal year 2024.

What is Aptevo Therapeutics Inc's earnings per share (EPS)?

Aptevo Therapeutics Inc (APVO) reported diluted earnings per share of $-87.38 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Aptevo Therapeutics Inc's EBITDA?

Aptevo Therapeutics Inc (APVO) had EBITDA of -$24.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Aptevo Therapeutics Inc's operating cash flow?

Aptevo Therapeutics Inc (APVO) generated -$23.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Aptevo Therapeutics Inc's total assets?

Aptevo Therapeutics Inc (APVO) had $15.6M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Aptevo Therapeutics Inc spend on research and development?

Aptevo Therapeutics Inc (APVO) invested $14.4M in research and development during fiscal year 2024.

How many shares does Aptevo Therapeutics Inc have outstanding?

Aptevo Therapeutics Inc (APVO) had 1M shares outstanding as of fiscal year 2024.

What is Aptevo Therapeutics Inc's current ratio?

Aptevo Therapeutics Inc (APVO) had a current ratio of 1.72 as of fiscal year 2024, which is generally considered healthy.

What is Aptevo Therapeutics Inc's debt-to-equity ratio?

Aptevo Therapeutics Inc (APVO) had a debt-to-equity ratio of 2.28 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Aptevo Therapeutics Inc's return on assets (ROA)?

Aptevo Therapeutics Inc (APVO) had a return on assets of -154.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Aptevo Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Aptevo Therapeutics Inc (APVO) had $8.7M in cash against an annual operating cash burn of $23.8M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Aptevo Therapeutics Inc's Piotroski F-Score?

Aptevo Therapeutics Inc (APVO) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Aptevo Therapeutics Inc's earnings high quality?

Aptevo Therapeutics Inc (APVO) has an earnings quality ratio of 0.99x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.